Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to purchase an aggregate of 221,000 shares of common stock to six newly hired employees on May 28, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $29.34, matching the Nasdaq Global Select Market closing price on the grant date, a 10-year term, and vest over four years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) will participate in the 2026 Jefferies Global Healthcare Conference in early June 2026. The company’s President and CEO, Yujiro S. Hata, will join a fireside chat and an AI panel, both accessible via webcast on IDEAYA’s investor website.
IDEAYA (Nasdaq: IDYA) reported Q1 2026 results and a business update highlighting a pivotal clinical win and strong liquidity. The Phase 2/3 OptimUM-02 darovasertib combination met its primary endpoint (HR 0.42; median PFS 6.9 vs 3.1 months).
The company plans an NDA submission in H2 2026 under FDA RTOR, multiple H2 2026 data readouts, and reported $972.9M cash as of March 31, 2026 with runway into 2030.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to five newly hired employees on April 30, 2026 under its 2023 Inducement Plan. An aggregate of 237,800 options were granted at an exercise price of $29.10 per share, equal to the April 30 closing price.
The options have a 10-year term and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA (NASDAQ: IDYA) will initiate an FDA RTOR submission for darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma following positive Phase 2/3 OptimUM-02 topline results. The trial met its primary endpoint: PFS 6.9 vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001).
IDEAYA plans the first RTOR pre-submission in May and expects NDA completion in H2 2026; full results to be presented at ASCO 2026.
IDEAYA Biosciences (Nasdaq: IDYA) will present complete Phase 2/3 registrational data from the OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma at ASCO 2026.
The late-breaking oral presentation (LBA9503) is scheduled for June 1, 2026, 8-11AM CDT in the Melanoma/Skin Cancers session; Dr. Marlana Orloff will present additional data not included in prior topline disclosure.
IDEAYA (NASDAQ: IDYA) and Servier reported positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination improved median PFS to 6.9 months vs 3.1 months (HR 0.42; 95% CI 0.30-0.59; p<0.0001) and ORR to 37.1% vs 5.8% (p<0.0001), including five complete responses. Median DOR was 6.8 months. Safety was manageable with known adverse events; serious treatment-related events were single-digit percent. An NDA submission is planned for H2 2026 and full data will be presented at a major 2026 medical conference.
IDEAYA (NASDAQ: IDYA) will release topline results from the Phase 2/3 OptimUM-02 trial on Monday, April 13, 2026 at 8:00 a.m. ET. The trial evaluates darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma.
A joint IDEAYA and Servier pre-market release will be followed by a conference call and webcast; a replay will be available on IDEAYA's website for 30 days.
IDEAYA (NASDAQ: IDYA) announced first‑patient‑in for a Phase 1 dose‑escalation trial of IDE574, a potential first‑in‑class oral dual inhibitor of KAT6 and KAT7, on April 6, 2026. The trial will evaluate safety, pharmacokinetics, and monotherapy efficacy in solid tumors including breast, prostate, colorectal, and lung cancer.
IDE574 shows single‑digit to low‑teen nanomolar cellular potency, ~350‑to‑2,000x selectivity versus KAT5/KAT8, and superior preclinical monotherapy durability versus KAT6 selective inhibitors; a preclinical profile will be presented at AACR 2026.
IDEAYA (NASDAQ: IDYA) announced first-patient-in (FPI) for a Phase 1 combination study of IDE849 (DLL3-targeting TOP1 ADC) plus IDE161 (PARG inhibitor) in DLL3-upregulated solid tumors, including SCLC, NETs, NECs, and melanoma.
The ongoing global IDE849 Phase 1 program is evaluating 3.5 mg/kg IV Q3W in dose escalation and a 2.4 mg/kg IV Q3W expansion cohort where multiple RECIST v1.1 partial responses were observed; a clinical data update is planned for H2 2026.